Canaccord Genuity Group Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $3.00

Definitive Healthcare (NASDAQ:DH) had its target price reduced by Canaccord Genuity Group from $4.00 to $3.00 in a research report report published on Friday morning,Benzinga reports. They currently have a hold rating on the stock.

A number of other research firms have also recently weighed in on DH. Stephens decreased their target price on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, January 21st. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research report on Thursday, November 6th. Barclays reduced their price target on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a report on Monday, December 8th. Finally, Morgan Stanley reaffirmed an “underperform” rating and issued a $3.50 price objective on shares of Definitive Healthcare in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Definitive Healthcare has an average rating of “Hold” and an average target price of $3.52.

Definitive Healthcare Stock Down 8.6%

DH stock opened at $1.28 on Friday. The firm has a 50-day moving average price of $2.18 and a 200-day moving average price of $2.87. Definitive Healthcare has a 12 month low of $1.14 and a 12 month high of $4.70. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $180.94 million, a P/E ratio of -1.02 and a beta of 1.66.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue increased its position in Definitive Healthcare by 109.3% during the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after purchasing an additional 5,970 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Definitive Healthcare in the 2nd quarter valued at $32,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Definitive Healthcare during the fourth quarter worth $35,000. Savant Capital LLC bought a new position in Definitive Healthcare during the second quarter worth $45,000. Finally, SG Americas Securities LLC acquired a new position in Definitive Healthcare in the fourth quarter valued at $46,000. 98.67% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Definitive Healthcare

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.